Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ViroPharma has announced that ViroPharma and Wyeth Pharmaceuticals, a division of Wyeth, have jointly discontinued the development of HCV-796 due to the previously announced safety issue that emerged in the ongoing Phase II trial in patients with hepatitis C.
Subscribe to our email newsletter
The companies will ensure that patients enrolled in the ongoing Phase II study will continue to receive the current standard of care. ViroPharma also announced that ViroPharma and Wyeth do not expect to continue to collaborate on future development of hepatitis C treatment candidates.
Vincent Milano, president and CEO of ViroPharma, said: “Significant activities were undertaken to determine a clear path forward for HCV-796; however, the risk associated with potential hepatotoxicity ultimately posed too high of a hurdle to merit further development.”